axicabtagene ciloleucel
Sales of the firm's TROP2-directed antibody-drug conjugate climbed 56 percent year over year thanks to increased demand among breast and bladder cancer patients.
Bristol Myers Squibb's Breyanzi Nets Second-Line Lymphoma Approval in Europe
The European Commission approved the autologous CAR T-cell therapy for relapsed lymphoma patients following first-line chemo-immunotherapy.
Gilead Q1 Oncology Segment Sales Jump 59 Percent
Trodelvy sales increased 52 percent, Yescarta sales grew 70 percent, and Tecartus revenues increased 40 percent in Q1 2023 compared to the year-ago quarter.
NICE Backs Availability of Gilead's Yescarta, Tecartus Through Cancer Drugs Fund
The institute declined to recommend certain indications of the hematologic cancer drugs last year, but will collect additional data on their efficacy through the Cancer Drugs Fund.
EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment
If approved in Europe, Breyanzi would compete with Gilead Sciences' CAR T-cell therapy Yescarta, which netted second-line LBCL approval in Europe last fall.